{"id":"alks-8700","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL3989944","moleculeType":"Small molecule","molecularWeight":"255.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALKS 8700 combines two antipsychotic agents: aripiprazole (a partial dopamine D2 receptor agonist) and flupenthixol decanoate (a typical antipsychotic with dopamine antagonist properties). The combination is formulated as a long-acting injectable to improve medication adherence and provide continuous antipsychotic coverage in patients with schizophrenia or bipolar disorder.","oneSentence":"ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:20.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder"}]},"trialDetails":[{"nctId":"NCT02634307","phase":"PHASE3","title":"A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-12-10","conditions":"Multiple Sclerosis","enrollment":1057},{"nctId":"NCT03093324","phase":"PHASE3","title":"A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-03-15","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":506},{"nctId":"NCT02201849","phase":"PHASE1","title":"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALKS 8700","genericName":"ALKS 8700","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation. Used for Schizophrenia, Bipolar I disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}